Antiplatelet

Question 1

Eptifibatide

Answer 1

Glycoprotein IIb/IIIa inhibitors

SAS product

Prevent binding of fibrinogen to platelet, by occupying glycoprotein IIb/IIIa receptor, thereby blocking platelet aggregation. Tirofiban is a non-peptide antagonist; eptifibatide is a cyclic heptapeptide.

Question 2

Tirofiban

Answer 2

Glycoprotein IIb/IIIa inhibitors

Prevent binding of fibrinogen to platelet, by occupying glycoprotein IIb/IIIa receptor, thereby blocking platelet aggregation. Tirofiban is a non-peptide antagonist; eptifibatide is a cyclic heptapeptide.

Question 3

Clopidogrel

Answer 3

P2Y12 antagonists

The active metabolite of the thienopyridines (clopidogrel, prasugrel) irreversibly binds to the platelet P2Y12 receptor and inhibits platelet aggregation for the life of the platelet. Ticagrelor binds reversibly to the P2Y12 receptor.

Question 4

Prasugrel

Answer 4

P2Y12 antagonists

The active metabolite of the thienopyridines (clopidogrel, prasugrel) irreversibly binds to the platelet P2Y12 receptor and inhibits platelet aggregation for the life of the platelet. Ticagrelor binds reversibly to the P2Y12 receptor.

Question 5

Ticagrelor

Answer 5

P2Y12 antagonists

The active metabolite of the thienopyridines (clopidogrel, prasugrel) irreversibly binds to the platelet P2Y12 receptor and inhibits platelet aggregation for the life of the platelet. Ticagrelor binds reversibly to the P2Y12 receptor.

Question 6

Aspirin

Answer 6

Inhibits platelet aggregation by irreversibly inhibiting cyclo-oxygenase, reducing the synthesis of thromboxane A2 (an inducer of platelet aggregation) for the life of the platelet.

Question 7

Dipyridamole

Answer 7

Inhibits platelet function by inhibiting phosphodiesterase, which increases platelet cAMP; also inhibits endogenous adenosine reuptake causing coronary vasodilation.